Publications from OUS - Lymphoma biology group

119 publications found

Publications 2020

  1. Bai B, Myklebust JH, Wälchli S (2020)
    Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
    Methods Mol Biol, 2115, 445-454
    DOI 10.1007/978-1-0716-0290-4_25, PubMed 32006416
  2. Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
    Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
    Br J Haematol, 189 (4), 661-671
    DOI 10.1111/bjh.16425, PubMed 32017050
  3. Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL (2020)
    Tuning the Antigen Density Requirement for CAR T-cell Activity
    Cancer Discov, 10 (5), 702-723
    DOI 10.1158/2159-8290.CD-19-0945, PubMed 32193224
  4. Rein ID, Notø HØ, Bostad M, Huse K, Stokke T (2020)
    Cell Cycle Analysis and Relevance for Single-Cell Gating in Mass Cytometry
    Cytometry A, 97 (8), 832-844
    DOI 10.1002/cyto.a.23960, PubMed 31943748
  5. Sonnet F, Namork E, Stylianou E, Gaare-Olstad I, Huse K, Andorf S, Mjaaland S, Dirven H, Nygaard U (2020)
    Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food
    BMC Immunol, 21 (1), 43
    DOI 10.1186/s12865-020-00373-w, PubMed 32698761
  6. Winge-Main AK, Wälchli S, Marit Inderberg E (2020)
    T-cell receptor therapy (TCR) against melanoma -immunotherapy for the future?
    Scand J Immunol, e12927 (in press)
    DOI 10.1111/sji.12927, PubMed 32640053
  7. Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
    Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
    Blood Adv, 4 (9), 1859-1866
    DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

  1. Huse K (2019)
    Expanding the Clinical Cytometry Toolbox-Receptor Occupancy by Mass Cytometry
    Cytometry A, 95 (10), 1046-1048
    DOI 10.1002/cyto.a.23784, PubMed 31046178
  2. Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM (2019)
    Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response
    Cytometry A, 95 (4), 442-449
    DOI 10.1002/cyto.a.23737, PubMed 30838773
  3. Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
    TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
    Cancer Immunol Res, 7 (3), 355-362
    DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053
  4. Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
    Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
    Blood Adv, 3 (8), 1230-1243
    DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
  5. Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
    NK cells specifically TCR-dressed to kill cancer cells
    EBioMedicine, 40, 106-117
    DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853
  6. Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
    A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
    Haematologica, 104 (10), e460-e464
    DOI 10.3324/haematol.2018.209080, PubMed 30846496

Publications 2018

  1. Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
    The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
    Br J Haematol, 183 (2), 225-234
    DOI 10.1111/bjh.15518, PubMed 30080252
  2. Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM (2018)
    Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
    Blood, 132 (22), 2401-2405
    DOI 10.1182/blood-2018-05-851154, PubMed 30257882
  3. Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
    Artesunate shows potent anti-tumor activity in B-cell lymphoma
    J Hematol Oncol, 11 (1), 23
    DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

  1. Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH (2017)
    BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5
    PLoS One, 12 (5), e0177188
    DOI 10.1371/journal.pone.0177188, PubMed 28489883
  2. Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
    Human c-SRC kinase (CSK) overexpression makes T cells dummy
    Cancer Immunol Immunother, 67 (4), 525-536
    DOI 10.1007/s00262-017-2105-9, PubMed 29248956
  3. Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
    T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
    Oncoimmunology, 6 (4), e1302631
    DOI 10.1080/2162402X.2017.1302631, PubMed 28507809
  4. Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
    T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
    Clin Cancer Res, 24 (4), 870-881
    DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528
  5. Koksal H, Walchli S (2017)
    Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?
    Transl. Cancer Res., 6 3, S622-S624
  6. Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C et al. (2017)
    New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
    J Clin Oncol, 35 (15), 1668-1677
    DOI 10.1200/JCO.2016.70.7901, PubMed 28291392
  7. Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J (2017)
    Defective IL-4 signaling in T cells defines severe common variable immunodeficiency
    J Autoimmun, 81, 110-119
    DOI 10.1016/j.jaut.2017.04.004, PubMed 28476239
  8. Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
    A TCR-based Chimeric Antigen Receptor
    Sci Rep, 7 (1), 10713
    DOI 10.1038/s41598-017-11126-y, PubMed 28878363
  9. Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K (2017)
    Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
    Cytometry B Clin Cytom, 92 (1), 79-87
    DOI 10.1002/cyto.b.21498, PubMed 27933753

Publications 2016

  1. Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M (2016)
    Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants
    Mol Ther, 24 (9), 1675-85
    DOI 10.1038/mt.2016.134, PubMed 27377043
  2. Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
    The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
    Br J Haematol, 175 (1), 102-14
    DOI 10.1111/bjh.14201, PubMed 27341313
  3. Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK (2016)
    Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
    Immunology, 149 (1), 62-73
    DOI 10.1111/imm.12629, PubMed 27278254
  4. Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
    T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
    Oncoimmunology, 5 (12), e1249090
    DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
  5. Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J (2016)
    Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
    Oncoimmunology, 5 (5), e1138199
    DOI 10.1080/2162402X.2016.1138199, PubMed 27467957
  6. Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R (2016)
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
    Blood, 129 (6), 759-770
    DOI 10.1182/blood-2016-05-718494, PubMed 28011673
  7. Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B (2016)
    Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency
    Clin Immunol, 175, 69-74
    DOI 10.1016/j.clim.2016.11.014, PubMed 27919819

Publications 2015

  1. Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H (2015)
    Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
    Histopathology, 67 (1), 62-9
    DOI 10.1111/his.12624, PubMed 25431344
  2. Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A (2015)
    Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma
    Biol Blood Marrow Transplant, 21 (5), 840-7
    DOI 10.1016/j.bbmt.2014.12.027, PubMed 25689789
  3. Dale Rein I, Stokke C, Jalal M, Myklebust JH, Patzke S, Stokke T (2015)
    New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX
    Cell Cycle, 14 (20), 3261-9
    DOI 10.1080/15384101.2015.1087617, PubMed 26317799
  4. Oksvold MP (2015)
    Incidence of Data Duplications in a Randomly Selected Pool of Life Science Publications
    Sci Eng Ethics, 22 (2), 487-96
    DOI 10.1007/s11948-015-9668-7, PubMed 26065681
  5. Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY (2015)
    The targeting of human and mouse B lymphocytes by dasatinib
    Exp Hematol, 43 (5), 352-363.e4
    DOI 10.1016/j.exphem.2015.01.008, PubMed 25641047
  6. Oksvold MP, Neurauter A, Pedersen KW (2015)
    Magnetic bead-based isolation of exosomes
    Methods Mol Biol, 1218, 465-81
    DOI 10.1007/978-1-4939-1538-5_27, PubMed 25319668
  7. Polikowsky HG, Wogsland CE, Diggins KE, Huse K, Irish JM (2015)
    Cutting Edge: Redox Signaling Hypersensitivity Distinguishes Human Germinal Center B Cells
    J Immunol, 195 (4), 1364-1367
    DOI 10.4049/jimmunol.1500904, PubMed 26157177
  8. Tadesse FG, Mensali N, Fallang LE, Walseng E, Yang W, Olweus J, Wälchli S (2015)
    Unpredicted phenotypes of two mutants of the TcR DMF5
    J Immunol Methods, 425, 37-44
    DOI 10.1016/j.jim.2015.06.006, PubMed 26079729
  9. Theodossiou TA, Wälchli S, Olsen CE, Skarpen E, Berg K (2015)
    Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity
    ACS Chem Biol, 11 (1), 251-62
    DOI 10.1021/acschembio.5b00734, PubMed 26569462
  10. Walseng E, Wälchli S, Fallang LE, Yang W, Vefferstad A, Areffard A, Olweus J (2015)
    Soluble T-cell receptors produced in human cells for targeted delivery
    PLoS One, 10 (4), e0119559
    DOI 10.1371/journal.pone.0119559, PubMed 25875651

Publications 2014

  1. Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
    A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
    PLoS One, 9 (9), e104249
    DOI 10.1371/journal.pone.0104249, PubMed 25226156
  2. Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A, Pedersen KW (2014)
    Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells
    Clin Ther, 36 (6), 847-862.e1
    DOI 10.1016/j.clinthera.2014.05.010, PubMed 24952935
  3. Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
    Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
    Haematologica, 100 (2), 238-45
    DOI 10.3324/haematol.2014.113472, PubMed 25381134
  4. Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A et al. (2014)
    Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms
    Cancer Discov, 4 (4), 480-93
    DOI 10.1158/2159-8290.CD-13-0915, PubMed 24491438

Publications 2013

  1. Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
    Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma
    PLoS One, 8 (11), e79602
    DOI 10.1371/journal.pone.0079602, PubMed 24260260
  2. Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
    Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma
    Epigenetics, 9 (3), 428-36
    DOI 10.4161/epi.27554, PubMed 24362313
  3. Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF (2013)
    Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation
    Eur J Immunol, 44 (3), 774-84
    DOI 10.1002/eji.201343671, PubMed 24293164
  4. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
    Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
    Leuk Lymphoma, 54 (10), 2205-14
    DOI 10.3109/10428194.2013.774392, PubMed 23391141

Publications 2012

  1. Bakkebø M, Huse K, Hilden VI, Forfang L, Myklebust JH, Smeland EB, Oksvold MP (2012)
    SARA is dispensable for functional TGF-β signaling
    FEBS Lett, 586 (19), 3367-72
    DOI 10.1016/j.febslet.2012.07.027, PubMed 22819827
  2. Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A (2012)
    Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
    Br J Haematol, 159 (5), 604-8
    DOI 10.1111/bjh.12073, PubMed 23043253
  3. Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH (2012)
    Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma
    PLoS One, 7 (10), e46117
    DOI 10.1371/journal.pone.0046117, PubMed 23049692
  4. Oksvold MP, Pedersen NM, Forfang L, Smeland EB (2012)
    Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling
    FEBS Lett, 586 (20), 3575-81
    DOI 10.1016/j.febslet.2012.08.022, PubMed 22971756
  5. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
    Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
    Leuk Lymphoma, 53 (10), 1934-44
    DOI 10.3109/10428194.2012.682307, PubMed 22475179

Publications 2011

  1. Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, Stokke T, Smeland EB, Myklebust JH (2011)
    Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7
    Eur J Immunol, 41 (11), 3135-45
    DOI 10.1002/eji.201141558, PubMed 21898381

Publications 2010

  1. Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP (2010)
    TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK
    BMC Immunol, 11, 57
    DOI 10.1186/1471-2172-11-57, PubMed 21092277
  2. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
    Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
    Blood, 116 (9), 1489-97
    DOI 10.1182/blood-2010-03-272278, PubMed 20505157
  3. Smeland EB, Vartdal F, Wisløff F (2010)
    [Leadership and academic competence]
    Tidsskr Nor Laegeforen, 130 (6), 591
    DOI 10.4045/tidsskr.10.0217, PubMed 20348994
  4. Smeland EB, Vartdal F, Wisløff F (2010)
    [Close cooperation, but not oversteering]
    Tidsskr Nor Laegeforen, 130 (6), 590-1
    DOI 10.4045/tidsskr.10.0153, PubMed 20348990

Publications 2007

  1. Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB (2007)
    Characterization of early stages of human B cell development by gene expression profiling
    J Immunol, 179 (6), 3662-71
    DOI 10.4049/jimmunol.179.6.3662, PubMed 17785802
  2. Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH (2007)
    Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
    Eur J Immunol, 37 (10), 2937-48
    DOI 10.1002/eji.200636759, PubMed 17899540

Publications 2006

  1. Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
    BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
    Exp Hematol, 34 (1), 72-81
    DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393
  2. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
    Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
    Leukemia, 20 (3), 539-42
    DOI 10.1038/sj.leu.2404094, PubMed 16437153
  3. Sivertsen EA, Hystad ME, Gutzkow KB, Døsen G, Smeland EB, Blomhoff HK, Myklebust JH (2006)
    PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells
    Br J Haematol, 135 (1), 117-28
    DOI 10.1111/j.1365-2141.2006.06252.x, PubMed 16965383

Publications 2005

  1. Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005)
    BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
    BMC Immunol, 6, 9
    DOI 10.1186/1471-2172-6-9, PubMed 15877825

Publications 2004

  1. Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
    Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
    Cancer Immunol Immunother, 53 (12), 1119-26
    DOI 10.1007/s00262-004-0558-0, PubMed 15185015
  2. Moe JF, Sivertsen E, van Thanh D (2004)
    Adapting email functionality for mobile terminals
    LECT NOTES COMPUT SC, 3283, 199-206

Publications 2002

  1. Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB (2002)
    Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells
    Exp Hematol, 30 (9), 990-1000
    DOI 10.1016/s0301-472x(02)00868-8, PubMed 12225790

Publications 2000

  1. Myklebust JH, Smeland EB, Josefsen D, Sioud M (2000)
    Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow
    Blood, 95 (2), 510-8
    DOI 10.1182/blood.V95.2.510, PubMed 10627456

Publications 1999

  1. Myklebust JH, Josefsen D, Blomhoff HK, Levy FO, Naderi S, Reed JC, Smeland EB (1999)
    Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression
    J Cell Physiol, 180 (1), 71-80
    DOI 10.1002/(SICI)1097-4652(199907)180:1<71::AID-JCP8>3.0.CO;2-N, PubMed 10362019
  2. Smeland E (1999)
    [University function at the central hospital in Akershus]
    Tidsskr Nor Laegeforen, 119 (11), 1647
    PubMed 10385812

Publications 1997

  1. Smeland E (1997)
    [Changing physician's role]
    Tidsskr Nor Laegeforen, 117 (29), 4290
    PubMed 9441481

Publications 1996

  1. Schneider H, Huse K (1996)
    Arterial gene therapy
    Lancet, 348 (9038), 1380-1; author reply 1381-2
    DOI 10.1016/S0140-6736(05)65442-6, PubMed 8918290

Publications 1995

  1. Smeland E (1995)
    [Physicians liable for military service for sale]
    Tidsskr Nor Laegeforen, 115 (24), 3072
    PubMed 7570542

Publications 1994

  1. Smeland EB, Rusten L, Jacobsen SE, Skrede B, Blomhoff R, Wang MY, Funderud S, Kvalheim G, Blomhoff HK (1994)
    All-trans retinoic acid directly inhibits granulocyte colony-stimulating factor-induced proliferation of CD34+ human hematopoietic progenitor cells
    Blood, 84 (9), 2940-5
    DOI 10.1182/blood.V84.9.2940.bloodjournal8492940, PubMed 7524761

Publications 1992

  1. Smeland EB, Funderud S, Kvalheim G, Gaudernack G, Rasmussen AM, Rusten L, Wang MY, Tindle RW, Blomhoff HK, Egeland T (1992)
    Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells
    Leukemia, 6 (8), 845-52
    PubMed 1379314

Publications 1989

  1. Brinch L, Evensen SA, Stavem P, Smeland EB (1989)
    [Experiences of immunologic phenotyping in acute leukemia]
    Tidsskr Nor Laegeforen, 109 (4), 443-6
    PubMed 2919374
  2. Børresen AL, Brøgger A, Møller P, Smeland E (1989)
    [Gene technology in the prevention of cancer]
    Tidsskr Nor Laegeforen, 109 (33), 3430-4
    PubMed 2609305
  3. Smeland EB, Blomhoff HK, Funderud S, Shalaby MR, Espevik T (1989)
    Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes
    J Exp Med, 170 (4), 1463-8
    DOI 10.1084/jem.170.4.1463, PubMed 2677211
  4. Smeland EB, Godal T (1989)
    [The 1989 Nobel Prize in physiology and medicine]
    Tidsskr Nor Laegeforen, 109 (34-36), 3541-2
    PubMed 2694425

Publications 1988

  1. Smeland EB (1988)
    [The immunoglobulin gene superfamily]
    Tidsskr Nor Laegeforen, 108 (13), 1029-32, 1004
    PubMed 2455362
  2. Smeland EB (1988)
    [Cellular oncogenes. Role in normal cell growth and activation in neoplasms]
    Tidsskr Nor Laegeforen, 108 (16), 1299-303
    PubMed 3291192

Publications 1987

  1. Blomhoff HK, Smeland E, Mustafa AS, Godal T, Ohlsson R (1987)
    Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage
    Eur J Immunol, 17 (2), 299-301
    DOI 10.1002/eji.1830170224, PubMed 3030769
  2. Blomhoff HK, Smeland EB, Beiske K, Blomhoff R, Ruud E, Bjøro T, Pfeifer-Ohlsson S, Watt R, Funderud S, Godal T (1987)
    Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes
    J Cell Physiol, 131 (3), 426-33
    DOI 10.1002/jcp.1041310315, PubMed 3036888
  3. Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
    The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
    Int J Cancer, 39 (5), 590-4
    DOI 10.1002/ijc.2910390508, PubMed 3106247
  4. Piek J, Adelt T, Huse K, Bock WJ (1987)
    [Cerebrospinal fluid and plasma aminograms in patients with primary and secondary tumors of the CNS]
    Infusionsther Klin Ernahr, 14 (2), 73-7
    PubMed 3610311
  5. Smeland EB, Beiske K, Ohlsson R, Holte H, Ruud E, Blomhoff HK, Jefferis R, Godal T (1987)
    Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells
    J Immunol, 138 (10), 3179-84
    PubMed 3553323
  6. Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, Ohlsson R (1987)
    Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes
    Exp Cell Res, 171 (1), 213-22
    DOI 10.1016/0014-4827(87)90264-3, PubMed 2442015

Publications 1986

  1. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes O (1986)
    Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study
    Br Med J (Clin Res Ed), 293 (6556), 1195-9
    DOI 10.1136/bmj.293.6556.1195, PubMed 3096429
  2. Lea T, Smeland E, Funderud S, Vartdal F, Davies C, Beiske K, Ugelstad J (1986)
    Characterization of human mononuclear cells after positive selection with immunomagnetic particles
    Scand J Immunol, 23 (4), 509-19
    DOI 10.1111/j.1365-3083.1986.tb03083.x, PubMed 2422741
  3. Smeland EB, Godal T (1986)
    IgG subclasses in lymphomas
    Monogr Allergy, 19, 164-8
    PubMed 3762542
  4. Smeland EB, Godal T, Beiske K, Watt R, Pfeifer-Ohlsson S, Ohlsson R (1986)
    Regulation of c-myc mRNA and protein levels during activation of normal human B cells
    Curr Top Microbiol Immunol, 132, 290-6
    DOI 10.1007/978-3-642-71562-4_43, PubMed 3539537

Publications 1985

  1. Andersen HT, Smeland EB, Owe JO, Myhre K (1985)
    Analyses of maximum cardiopulmonary performance during exposure to acute hypoxia at simulated altitude--sea level to 5000 meters (760-404 mm Hg)
    Aviat Space Environ Med, 56 (12), 1192-7
    PubMed 4084174
  2. Godal T, Davies C, Smeland EB, Heikkilä R, Funderud S, Steen HB, Hildrum K (1985)
    Antibodies to surface IgM and IgD increase the expression of various class II antigens on human B cells
    Eur J Immunol, 15 (2), 173-7
    DOI 10.1002/eji.1830150212, PubMed 3871699
  3. Heikkilä R, Iversen JG, Smeland E, Godal T (1985)
    Intracellular Ca2+ buffering potentiates an 86Rb+ permeability response in human lymphocytes
    Acta Physiol Scand, 124 (2), 247-51
    DOI 10.1111/j.1748-1716.1985.tb07658.x, PubMed 3925725
  4. Smeland E, Funderud S, Ruud E, Kiil Blomhoff H, Godal T (1985)
    Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor
    Scand J Immunol, 21 (3), 205-14
    DOI 10.1111/j.1365-3083.1985.tb01422.x, PubMed 3887557
  5. Smeland E, Godal T, Ruud E, Beiske K, Funderud S, Clark EA, Pfeifer-Ohlsson S, Ohlsson R (1985)
    The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate
    Proc Natl Acad Sci U S A, 82 (18), 6255-9
    DOI 10.1073/pnas.82.18.6255, PubMed 3929253

Publications 1984

  1. Bjøro T, Gaarder PI, Smeland EB, Kornstad L (1984)
    Thyroid antibodies in blood donors: prevalence and clinical significance
    Acta Endocrinol (Copenh), 105 (3), 324-9
    DOI 10.1530/acta.0.1050324, PubMed 6702401
  2. Porstmann B, Porstmann T, Schmechta H, Nugel E, Huse K, Kopperschläger G, Seifert R (1984)
    Direct two-site binding enzyme immunoassay for human alpha-1-fetoprotein. Part I: Comparison of different peroxidase-IgG-conjugates and various reaction conditions
    Z Med Lab Diagn, 25 (1), 5-13
    PubMed 6202071
  3. Smeland EB, Jefferis R, Godal T (1984)
    Surface IgG subclasses in human B cell lymphomas as revealed by monoclonal antibodies
    Clin Exp Immunol, 57 (1), 163-70
    PubMed 6378459
  4. Smeland EB, Owe JO, Andersen HT (1984)
    Modification of the 'dividing bradycardia' by hypoxia or exercise
    Respir Physiol, 56 (2), 245-51
    DOI 10.1016/0034-5687(84)90108-7, PubMed 6463431

Publications 1983

  1. Huse K, Himmel M, Birkenmeier G, Bohla M, Kopperschläger G (1983)
    A novel purification procedure for human alpha-fetoprotein by application of immobilised Cibacron Blue F3G-A as affinity ligand
    Clin Chim Acta, 133 (3), 335-40
    DOI 10.1016/0009-8981(83)90280-2, PubMed 6194922
  2. Huse K, Kopperschläger G (1983)
    Interactions of antibodies against soluble phosphofructokinase with the soluble and particulate enzymes from yeast
    FEBS Lett, 155 (1), 50-4
    DOI 10.1016/0014-5793(83)80207-5, PubMed 6220923

Publications 1982

  1. Huse K, Kopperschläger G, Hofmann E (1982)
    A new procedure for the purification of proteinase B from baker's yeast and interaction of the purified enzyme with a specific inhibitor
    Acta Biol Med Ger, 41 (11), 991-1002
    PubMed 6763433

Publications 1981

  1. Huse K, Diening G (1981)
    [Anaesthesia and diabetes insipidus. A review (author's transl)]
    Anaesthesist, 30 (4), 159-65
    PubMed 7018319

Publications 1980

  1. Huse K, Leem W (1980)
    [Circulatory changes in neurosurgical patients with intracerebral angiomas in neuroleptanaesthesia (author's transl)]
    Anasth Intensivther Notfallmed, 15 (2), 144-51
    PubMed 7396101
  2. Huse K, Röhner G (1980)
    [Circulatory effects of dihydrazinophthalazine (Nepresol) compared with sodium nitroprusside in controlled hypotension. A study of neurosurgical patients under neuroleptanesthesia]
    Anasth Intensivther Notfallmed, 15 (2), 152-8
    PubMed 6772047
  3. Huse K, Schäffer R, Fistas G (1980)
    [Clinical experiences with diazepam (Valium) - fentanyl combination anesthesia in neurosurgery. A study of circulation and oxygen consumption]
    Anasth Intensivther Notfallmed, 15 (2), 135-43
    PubMed 6772046

Publications 1979

  1. Diezel W, Meffert H, Günther W, Huse K, Sönnichsen N (1979)
    [Exacerbation of systemic lupus erythematosus following UV irradiation--a hypothesis]
    Acta Biol Med Ger, 38 (9), 1301-6
    PubMed 399148
  2. Huse K, Wiecken H (1979)
    [Circulatory changes in the sitting position during neurosurgical anaesthesia (NLA) (author's transl)]
    Anaesthesist, 28 (12), 557-63
    PubMed 539650

Publications 1978

  1. Huse K, Stahl HJ, Krämer M (1978)
    [The effect of buprenorphin on circulation, respiration and the electroencephalogram (a postoperative study of 12 neurosurgical cases) (author's transl)]
    Prakt Anaesth, 13 (6), 489-94
    PubMed 740629

Publications 1977

  1. Diezel W, Meffert H, Günther W, Huse K, Sönnichsen N (1977)
    [Exacerbation of lupus erythematodes visceralis due to UV irradiation. Results and hypothetical aspects]
    Dermatol Monatsschr, 163 (4), 290-5
    PubMed 881079

Publications 1976

  1. Huse K, Kopperschläger G, Hofmann E (1976)
    Differences in the degradation of yeast phosphofructokinase by proteinases A and B from yeast
    Biochem J, 155 (3), 721-3
    DOI 10.1042/bj1550721, PubMed 133676
  2. Wüst HJ, Huse K, Lennartz H (1976)
    [Cardiovascular changes caused by atropine in normo- and hypothermic methoxyflurane anaesthesia (author's transl)]
    Anaesthesist, 25 (9), 418-24
    PubMed 970597

Publications 1974

  1. Huse K, Hartung E, Nadjmabadi MH (1974)
    [The effects of naloxone (Narcan) on circulation and respiration after neurolept anaesthesia for neurosurgical operations (author's transl)]
    Anaesthesist, 23 (11), 493-9
    PubMed 4458474
  2. Nadjmabadi MH, Huse K (1974)
    [Changes of the pah-plasma levels as a guideline for the renal circulation under the influence of various anaesthetic agents (author's transl)]
    Anaesthesist, 23 (1), 5-9
    PubMed 4458471

Publications 1972

  1. Huse K, Nicola E, Jeuken B (1972)
    [Changes of lactic and pyruvic acid levels in the cerebrospinal fluid as possible indicators for central hypoxia. Studies in hydrocephalic children]
    Neurochirurgia (Stuttg), 15 (6), 194-200
    DOI 10.1055/s-0028-1090542, PubMed 4655985
  2. Huse K, Röhner G (1972)
    [Hemodynamic changes in methoxyflurane anesthesia with controlled hypotension and hypothermia for neurosurgery]
    Zentralbl Neurochir, 33 (1), 19-33
    PubMed 5072148

 
Page visits: 7654